Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 Next >
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD RCUS
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD RCUS
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Provides Update on Phase 3 TROPiCS-04 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Tickers ACLX GILD
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces First Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD XLO
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD MRK
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD MRUS
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Tickers CBAY GILD
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.